MicroRNAs in T Cell-Immunotherapy

Sara G Dosil; Ana Rodríguez-Galán; Francisco Sánchez-Madrid; Lola Fernández-Messina

doi:10.3390/ijms24010250

MicroRNAs in T Cell-Immunotherapy

Int J Mol Sci. 2022 Dec 23;24(1):250. doi: 10.3390/ijms24010250.

Authors

Sara G Dosil^{1

2

3}, Ana Rodríguez-Galán^{1

2

3}, Francisco Sánchez-Madrid^{1

2

3

4}, Lola Fernández-Messina^{1

2

3

4

5}

Affiliations

¹ Immunology Service, Hospital Universitario de la Princesa, Instituto Investigación Sanitaria Princesa, 28006 Madrid, Spain.
² Intercellular Communication in the Inflammatory Response, Vascular Pathophysiology Area, National Center for Cardiovascular Research (CNIC), 28029 Madrid, Spain.
³ Universidad Autónoma de Madrid, 28049 Madrid, Spain.
⁴ Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.
⁵ Department of Cell Biology, Faculty of Biological Sciences, Universidad Complutense de Madrid, 28040 Madrid, Spain.

Abstract

MicroRNAs (miRNAs) act as master regulators of gene expression in homeostasis and disease. Despite the rapidly growing body of evidence on the theranostic potential of restoring miRNA levels in pre-clinical models, the translation into clinics remains limited. Here, we review the current knowledge of miRNAs as T-cell targeting immunotherapeutic tools, and we offer an overview of the recent advances in miRNA delivery strategies, clinical trials and future perspectives in RNA interference technologies.

Keywords: T cell immunotherapy; antagomiRNAs (antagomiRs); immunotherapy; miRNA delivery; microRNAs (miRNAs); nanomedicine; nanoparticles (NPs).

Publication types

Review

MeSH terms

Immunotherapy
MicroRNAs* / genetics
MicroRNAs* / therapeutic use
Precision Medicine
RNA Interference
T-Lymphocytes

Substances

MicroRNAs

Grants and funding

This manuscript was funded by grants AEI/10.13039/501100011033, PID-2020-120412RB-I100 and PDC2021-121797-I00 (F.S.-M.) from the Spanish Ministry of Economy and Competitiveness; CAM (S2017/BMD-3671-INFLAMUNE-CM) from the Comunidad de Madrid (F.S.-M.), CIBERCV (CB16/11/00272) and BIOIMID PIE13/041 from the Instituto de Salud Carlos “la Caixa” Foundation under the project code HR17-00016. The current research is supported by AECC-Coordinated Grant 2022 (PRYCO223002PEIN). The CNIC is supported by the Ministerio de Ciencia, Innovacion y Universidades and the Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). IMDEA Nanociencia acknowledges support from the ‘Severo Ochoa’ Programme for Centres of Excellence in R&D (MINECO, CEX2020-001039-S). S.G.D. is supported by a grant from the Spanish Ministry of Universities.